| Platform/Drug Candidate | Indication | Also Supports Sickle Cell & Osteoarthritis Clinical Focus? |
|---|---|---|
| VASPORTA™ | NA | Yes |
| VAS-101 (Vasceptor®) | Red Blood Cell Preservation & Storage | Yes |
| VAS-101 (Vasceptor®) | Hypertension | Yes |
| VAS-101 (Vasceptor®) | Anti-Aging/Dementia | Yes |
| Quesceptor™ | Hypertension | Yes |
| STO-1 | Brain Cancer – Glioblastoma | No |
| STO-2 | Pancreatic Cancer | No |
| Product | Company | Dosage Form | Mechanism of Action | Limitations | List Price | Commercial Comment |
|---|---|---|---|---|---|---|
| Hydroxyurea | Generic | Oral Capsule | Raises Fetal Hemoglobin | Poor compliance | $500–$1,000/year | Generic |
| Endari | Emmaus Life Sciences | Oral Powder | Regulates and prevents oxidative damage in the RBC | Poor compliance, difficult to take | >$40K/year | Generic available as of July 2024 |
| Adakveo | Novartis | IV Infusion | P-selectin blocker, prevents RBC from sticking | Serious adverse events and side effects | >$100K/year | Future uncertain, withdrawn from EU in Aug 2023 |
| Voxelotor | Pfizer | Oral Tablets | Inhibits HbS polymerization | Serious side effects | >$100K/year | Withdrawn globally in Sept 2024 |
| Casgevy | Vertex | IV Infusion | Gene Editing | Cost prohibitive, very limited use | $2.2 million (one time) | One-time use |
| Lyfgenia | Bluebird Bio | IV Infusion | Gene Editing | Cost prohibitive, very limited use | $3.1 million (one time) | One-time use |
| Current Drugs for OA | MOA | Availability | Generic or RX |
|---|---|---|---|
| NSAIDs | Anti-inflammatory | OTC and Prescription | Generic Market |
| Prednisone | Immune Suppressant | Prescription Only | Generic Market |
| Gabapentin | Alters Brain Activity–Neurotransmitters | Prescription Only | Generic Market |
| Cymbalta | Alters Serotonin and Norepinephrine | Prescription Only | Generic Market |
| Muscle Relaxants | CNS Depressants | Prescription Only | Generic Market |
| OPIOIDS | Block Pain Signals in the Brain & Body | Prescription Only | Generic Market |
| Vasceptor®* | Multi Modal – Activator of SIRT1 & Nrf2 | Prescription Only | Branded |
| Patent no. | Date Issued | Description |
|---|---|---|
| US 11,484,493B2 | Nov 01, 2022 | Transdermal Delivery Formulations |
| US 11,786,456B2 | Oct 17, 2023 | Transdermal Delivery Formulations |
| US 11,786,561B2 | Oct 17, 2023 | Approach to Sustained Production and Delivery of Nitric Oxide and S-Nitrosothiols |
| US 11,786,712B2 | Oct 17, 2023 | Nitric Oxide Releasing Device |
| US 12,059,493B2 | Aug 13, 2024 | Transdermal Delivery Formulations |
| US 12,151,019 | Nov 26, 2024 | Composition for Blood Storage and Transfusions |
| Aus 2021373070 | Dec 07, 2024 | Transdermal Delivery Formulations |
| Brazil 2023008763-5 | Aug 27, 2024 | Transdermal Delivery Formulations |
| Japan 7613776 | Jan 06, 2025 | Transdermal Delivery Formulations |
| Patent no. | Date issued | Description |
|---|---|---|
| Australia 2025200403 | Filed Jan. 21, 2025 | Composition for Blood Storage and Transfusions |
| Australia 2023210558 | Filed Aug. 1, 2023 | Transdermal Delivery Formulations |
| Australia 2024227577 | Filed Oct. 24, 2024 | Transdermal Delivery Formulations |
| Brazil BR102025001090-9 | Filed Jan. 21, 2025 | Composition for Blood Storage and Transfusions |
| Brazil BR122025001904-6 | Filed Jan. 30, 2025 | Composition for Blood Storage and Transfusions |
| Brazil BR102024021784-5 | Filed Oct. 21, 2024 | Transdermal Delivery Formulations |
| Canada 3,262,113 | Filed Jan. 14, 2025 | Composition for Blood Storage and Transfusions |
| Australia 2025200403 | Filed Jan. 21, 2025 | Composition for Blood Storage and Transfusions |
| Canada 3,197,959 | Filed May 8, 2023 | Transdermal Delivery Formulations |
| Canada 3,248,746 | Filed Oct. 11, 2024 | Transdermal Delivery Formulations |
| China 2025101104947 | Filed Jan. 23, 2025 | Composition for Blood Storage and Transfusions |
| China 2024114946205 | Filed Oct. 24, 2024 | Transdermal Delivery Formulations |
| Europe 25153578.7 | Filed Jan. 23, 2025 | Composition for Blood Storage and Transfusions |
| Europe 21890283.1 | Filed June 5, 2023 | Transdermal Delivery Formulations |
| Europe 24207047.2 | Filed Oct. 16, 2024 | Transdermal Delivery Formulations |
| India 202514005418 | Filed Jan. 23, 2025 | Composition for Blood Storage and Transfusions |
| India 202317014748 | Filed Mar. 5, 2023 | Transdermal Delivery Formulations |
| India 202414078052 | Filed Oct. 15, 2024 | Transdermal Delivery Formulations |
| Japan 2025-008944 | Filed Jan. 22, 2025 | Composition for Blood Storage and Transfusions |
| Japan 2024-157891 | Filed Sep. 12, 2024 | Transdermal Delivery Formulations |
| Japan 2024-180836 | Filed Oct. 16, 2024 | Transdermal Delivery Formulations |
| Korea 10-2025-0010243 | Filed Jan. 23, 2025 | Composition for Blood Storage and Transfusions |
| Korea 10-2024-0143285 | Filed Oct. 18, 2024 | Transdermal Delivery Formulations |
| Mexico MX/a/2025/000897 |
Filed Jan. 22, 2025 | Composition for Blood Storage and Transfusions |
| Mexico MX/a/2024/012712 |
Filed Oct. 14, 2024 | Transdermal Delivery Formulations |
| Nigeria (not yet assigned) | Filed Jan. 21, 2025 | Composition for Blood Storage and Transfusions |
| Nigeria F/PT/C/O/2024/14827 |
Filed Oct. 16, 2023 | Transdermal Delivery Formulations |
| U.S. 18/487,659 | Filed Oct. 16, 2023 | Nitric Oxide Releasing Device |
| U.S. 18/487,635 | Filed Oct. 16, 2023 | Approach to Sustained Production and Delivery of Nitric Oxide and S-Nitrosothiols |
| U.S. 18/051,266 | Filed Oct. 31, 2022 | Transdermal Delivery Formulations |
| U.S.18/487,668 | Filed Oct. 16, 2023 | Transdermal Delivery Formulations |
| U.S. 18/794,030 | Filed Aug. 5, 2024 | Transdermal Delivery Formulations |
| U.S. 18/944,844 | Filed Nov. 12, 2024 | Transdermal Delivery Formulations |
| India 202514005418 | Filed Jan. 23, 2025 | Composition for Blood Storage and Transfusions |
| India 202317014748 | Filed Mar. 5, 2023 | Transdermal Delivery Formulations |
| India 202414078052 | Filed Oct. 15, 2024 | Transdermal Delivery Formulations |
| Japan 2025-008944 | Filed Jan. 22, 2025 | Composition for Blood Storage and Transfusions |
| Japan 2024-157891 | Filed Sep. 12, 2024 | Transdermal Delivery Formulations |
| Japan 2024-180836 | Filed Oct. 16, 2024 | Transdermal Delivery Formulations |
how can we change no. of columns in product category page in woocommerce
Innovating treatments for chronic diseases via transdermal loading of drugs into circulating blood cells for targeted anti-inflammatory activity.
Innovating treatments for chronic diseases via transdermal loading of drugs into circulating blood cells for targeted anti-inflammatory activity.
Vascarta is a clinical-stage pharmaceutical company built on three core assets designed to increase therapeutic effectiveness while improving the patient experience.
Leading areas of study are Sickle Cell disease, Osteoarthritis, Dementia, and Cancer.
Vasporta™ Transdermal Delivery
A patented topical system that enhances absorption, bypasses oral bioavailability issues, and offers a needle-free alternative to injections.
OUR LEAD PRODUCT
CANDIDATE: VAS-101
Harnesses the established anti-inflammatory and pain-relieving properties of curcumin through transdermal delivery which overcomes the limited bioavailability and effectiveness of oral dosing. Phase 1 clinical trials for Sickle Cell Disease and Osteoarthritis initiated 1Q2025 with expected completion by 4Q2025.
Targeted
Cancer
Therapeutics
Novel linker chemistry licensed from CUNY that combines curcumin with approved cancer drugs to improve efficacy and reduce side effects.
- Curcumin is an anti-inflammatory compound often used to treat pain-related conditions, including osteoarthritis (OA). In a recent meta-analysis, it was concluded that based on the results of 23 studies and 2175 patients with knee OA, compared to a placebo, the oral administration of curcumin reduced self-reported pain as measured by the visual analogue scale pain score, and Western Ontario and McMaster Universities Arthritis Index. Moreover, compared with NSAIDs, curcumin alone and curcumin + NSAIDs (OR = 0.23, 95% CI: 0.06 to 0.9) had a reduced incidence of adverse reactions.
- Efficacy and safety of curcumin therapy for knee osteoarthritis: A Bayesian network meta-analysis
- Although effectiveness against OA has been seen with curcumin taken orally, the therapeutic benefits of oral curcumin are limited due to its poor bioavailability (e.g., poorly absorbed; rapidly excreted) providing a clear rationale to topically/transdermally test Vasceptor® against OA. In this unpublished study, curcumin was not detected in blood or plasma after the oral ingestion of curcumin; however, it was detected in blood for up to 6 hours after the transdermal delivery of Vasceptor®.
- Additional rationale for testing Vasceptor® include the many improvements in biomarkers of inflammation seen in rodent studies.
- Curcumin is an anti-inflammatory compound often used to treat pain-related conditions, including osteoarthritis (OA). In a recent meta-analysis, it was concluded that based on the results of 23 studies and 2175 patients with knee OA, compared to a placebo, the oral administration of curcumin reduced self-reported pain as measured by the visual analogue scale pain score, and Western Ontario and McMaster Universities Arthritis Index. Moreover, compared with NSAIDs, curcumin alone and curcumin + NSAIDs (OR = 0.23, 95% CI: 0.06 to 0.9) had a reduced incidence of adverse reactions.
- Efficacy and safety of curcumin therapy for knee osteoarthritis: A Bayesian network meta-analysis
- Although effectiveness against OA has been seen with curcumin taken orally, the therapeutic benefits of oral curcumin are limited due to its poor bioavailability (e.g., poorly absorbed; rapidly excreted) providing a clear rationale to topically/transdermally test Vasceptor® against OA. In this unpublished study, curcumin was not detected in blood or plasma after the oral ingestion of curcumin; however, it was detected in blood for up to 6 hours after the transdermal delivery of Vasceptor®.
- Additional rationale for testing Vasceptor® include the many improvements in biomarkers of inflammation seen in rodent studies.
Innovating treatments for chronic diseases via transdermal loading of drugs into circulating blood cells for targeted anti-inflammatory activity.
Vascarta is a clinical-stage pharmaceutical company built on three core assets designed to increase therapeutic effectiveness while improving the patient experience.
Leading areas of study are Sickle Cell disease, Osteoarthritis, Dementia, and Cancer.
Vasporta™ Transdermal Delivery
A patented topical system that enhances absorption, bypasses oral bioavailability issues, and offers a needle-free alternative to injections.
OUR LEAD
PRODUCT
CANDIDATE: VAS101
Harnesses the proven anti-inflammatory efficacy of curcumin through transdermal delivery which overcomes the limited bioavailability of oral dosing.Phase 1 clinical trials for Sickle Cell Disease and Osteoarthritis initiated 1Q2025 with expected completion by 4Q2025.
Targeted
Cancer
Therapeutics
Novel linker chemistry licensed from CUNY that combines curcumin with approved cancer drugs to improve efficacy and reduce side effects.
Vascarta Sickle Cell Disease Research – Selected Key Findings
- An article published in the Proceedings of the National Academy of Sciences (PNAS) Nexus journal describes studies in which humanized sickle cell mice topically treated with Vasceptor® experienced reduced pain and inflammation and reduced nerve damage along with improved red blood cell stability and functionality.
- “Targeting sickle cell pathobiology and pain with novel transdermal curcumin”
https://academic.oup.com/pnasnexus/advance-article/doi/10.1093/pnasnexus/pgaf053/8010891?searchresult=1 - Pain is a central characteristic of SCD. As shown below in Chart C, in cold conditions, male mice treated with Vasceptor® became less sensitive to painful stimulation within 1 hour post treatment, while female mice treated with Vasceptor® (chart D) became less sensitive to painful stimulation at 14 days. In room temperature conditions, female mice treated with Vasceptor® (Chart B) became less sensitive to painful stimulation at 10 days and male mice at 14 days (Chart A).
[ninja_tables id="14468"]
[ninja_tables id="14470"]
[ninja_tables id="14605"]
| Patent No. | Date of Patent | Description |
|---|---|---|
| US 11,484,493B2 | Nov 01, 2022 | Transdermal Delivery Formulations |
| US 11,786,456B2 | Oct 17, 2023 | Transdermal Delivery Formulations |
| US 11,786,561B2 | Oct 17, 2023 | Approach to Sustained Production and Delivery of Nitric Oxide and S-Nitrosothiols |
| US 11,786,712B2 | Oct 17, 2023 | Nitric Oxide Releasing Device |
| US 12,059,493B2 | Aug 13, 2024 | Transdermal Delivery Formulations |
| US 12,151,019 | Nov 26, 2024 | Composition for Blood Storage and Transfusions |
| Aus 2021373070 | Dec 07, 2024 | Transdermal Delivery Formulations |
| Brazil 2023008763-5 | Aug 27, 2024 | Transdermal Delivery Formulations |
| Japan 7613776 | Jan 06, 2025 | Transdermal Delivery Formulations |
| Australia 2025200403 | Filed Jan. 21, 2025 | Composition for Blood Storage and Transfusions |
| Australia 2023210558 | Filed Aug. 1, 2023 | Transdermal Delivery Formulations |
| Australia 2024227577 | Filed Oct. 24, 2024 | Transdermal Delivery Formulations |
| Brazil BR102025001090-9 | Filed Jan. 21, 2025 | Composition for Blood Storage and Transfusions |
| Brazil BR122025001904-6 | Filed Jan. 30, 2025 | Composition for Blood Storage and Transfusions |
| Brazil BR102024021784-5 | Filed Oct. 21, 2024 | Transdermal Delivery Formulations |
| Canada 3,262,113 | Filed Jan. 14, 2025 | Composition for Blood Storage and Transfusions |
| Australia 2025200403 | Filed Jan. 21, 2025 | Composition for Blood Storage a-nd Transfusions |
| Canada 3,197,959 | Filed May 8, 2023 | Transdermal Delivery Formulations |
| Canada 3,248,746 | Filed Oct. 11, 2024 | Transdermal Delivery Formulations |
| China 2025101104947 | Filed Jan. 23, 2025 | Composition for Blood Storage and Transfusions |
| China 2024114946205 | Filed Oct. 24, 2024 | Transdermal Delivery Formulations |
| Europe 25153578.7 | Filed Jan. 23, 2025 | Composition for Blood Storage and Transfusions |
| Europe 21890283.1 | Filed June 5, 2023 | Transdermal Delivery Formulations |
| Europe 24207047.2 | Filed Oct. 16, 2024 | Transdermal Delivery Formulations |
| India 202514005418 | Filed Jan. 23, 2025 | Composition for Blood Storage and Transfusions |
| India 202317014748 | Filed Mar. 5, 2023 | Transdermal Delivery Formulations |
| India 202414078052 | Filed Oct. 15, 2024 | Transdermal Delivery Formulations |
| Japan 2025-008944 | Filed Jan. 22, 2025 | Composition for Blood Storage and Transfusions |
| Japan 2024-157891 | Filed Sep. 12, 2024 | Transdermal Delivery Formulations |
| Japan 2024-180836 | Filed Oct. 16, 2024 | Transdermal Delivery Formulations |
| Korea 10-2025-0010243 | Filed Jan. 23, 2025 | Composition for Blood Storage and Transfusions |
| Korea 10-2024-0143285 | Filed Oct. 18, 2024 | Transdermal Delivery Formulations |
| Mexico MX/a/2025/000897 |
Filed Jan. 22, 2025 | Composition for Blood Storage and Transfusions |
| Mexico MX/a/2024/012712 |
Filed Oct. 14, 2024 | Transdermal Delivery Formulations |
| Nigeria (not yet assigned) | Filed Jan. 21, 2025 | Composition for Blood Storage and Transfusions |
| Nigeria F/PT/C/O/2024/14827 |
Filed Oct. 16, 2023 | Transdermal Delivery Formulations |
| U.S. 18/487,659 | Filed Oct. 16, 2023 | Nitric Oxide Releasing Device |
| U.S. 18/487,635 | Filed Oct. 16, 2023 | Approach to Sustained Production and Delivery of Nitric Oxide and S-Nitrosothiols |
| U.S. 18/051,266 | Filed Oct. 31, 2022 | Transdermal Delivery Formulations |
| U.S.18/487,668 | Filed Oct. 16, 2023 | Transdermal Delivery Formulations |
| U.S. 18/794,030 | Filed Aug. 5, 2024 | Transdermal Delivery Formulations |
| U.S. 18/944,844 | Filed Nov. 12, 2024 | Transdermal Delivery Formulations |
| India 202514005418 | Filed Jan. 23, 2025 | Composition for Blood Storage and Transfusions |
| India 202317014748 | Filed Mar. 5, 2023 | Transdermal Delivery Formulations |
| India 202414078052 | Filed Oct. 15, 2024 | Transdermal Delivery Formulations |
| Japan 2025-008944 | Filed Jan. 22, 2025 | Composition for Blood Storage and Transfusions |
| Japan 2024-157891 | Filed Sep. 12, 2024 | Transdermal Delivery Formulations |
| Japan 2024-180836 | Filed Oct. 16, 2024 | Transdermal Delivery Formulations |
VASCARTA CLINICAL DEVELOPMENT STATUS BY HEALTH CONDITION
Vasceptor® improves key heart biomarkers – p16 and il-1b
Statistical Significance levels: *p<0.05, **p<0.01
- As a result of these and other findings, the authors of a soon-to-be published manuscript write, “This effect of late-onset curcumin is somewhat reminiscent of rapamycin, which also has immune-modulating effects, and remains the most robust gerotherapeutic, with the most compelling evidence of efficacy among compounds initiated at middle to older ages.”
Brain Cancer/Glioblastoma
Disease Background
- Brain cancer is a malignant tumor that develops when abnormal cells in the brain grow out of control. It can be life-threatening because it can damage the brain’s vital structures. Glioblastoma is a fast-growing, aggressive, and deadly brain tumor that can affect people of any age. It is the most common primary brain cancer in adults.
- The overall 5-year survival rate for brain cancer is around 36%, meaning that roughly 36% of people diagnosed with a brain tumor will be alive 5 years after diagnosis; however, this rate varies significantly depending on the type of brain tumor and the patient’s age, with more aggressive tumors like glioblastoma having a much lower survival rate (around 5%).
- There is unmet medical need to improve the survivability of brain cancers like glioblastoma.
Anti-Cancer Linker Chemistry Background
- City University of New York’s (CUNY) novel, patent-pending technology exclusively licensed by Vascarta involves linking proven anti-cancer therapeutics such as paclitaxel (Taxol®), gemcitabine (Gemzar®), doxorubicin (Adriamycin®), and methotrexate (Jylamvo®) with curcumin. Linking the anti-cancer agents to curcumin optimizes the effectiveness of both agents. The linker breaks once the compound enters a cell (and is safely excreted?).
- The curcumin-linked compounds can overcome many of the limitations of conventional chemotherapies, including by:
- Activating the beneficial immune system within the tumor environment without triggering systemic autoimmune responses
- Delivering anti-oxidant and anti-inflammatory properties that reduce typical negative side effects such as nausea, fatigue, nerve damage, appetite loss, brain fog, etc.
- Crossing the blood-brain barrier that prevents most chemotherapeutics from being effective against brain tumors such as glioblastomas.
- Offering in many cases a more convenient topical application usage experience versus intravenous infusion.
Vascarta-licensed Brain Cancer/Glioblastoma Technology – Key Finding To Date
- Initial results from testing in typically incurable glioblastoma brain tumors have been extremely positive. Mice were implanted with glioblastoma tumors. Some of the mice were injected with the novel compound STO-1 which links the proven anti-cancer therapeutic Taxol® (Paclitaxel or “PAC”) with curcumin while other mice were injected with a placebo.
- As shown below, all of the mice injected with placebo died in less than 45 days. However, 2/3rds of the mice receiving STO-1 remained alive through 85 days when the experiment ended, and these mice were sacrificed.
- This is a remarkably encouraging result in glioblastoma, where survivability is typically minimal.
Pancreatic Cancer
Disease Background
- Pancreatic cancer is a type of cancer that forms in the pancreas, a gland that produces digestive enzymes and hormones. It is often difficult to diagnose early, and most people are diagnosed when the cancer has spread to other organs.
- According to the American Cancer Society the relative 5-year survival rate for pancreatic cancer is around 13%, although this rate varies depending on the degree to which the cancer has spread when diagnosed.
- There is unmet medical need to improve the survivability of pancreatic cancer.
Anti-Cancer Linker Chemistry Background
- City University of New York’s (CUNY) novel, patent-pending technology exclusively licensed by Vascarta involves linking proven anti-cancer therapeutics such as paclitaxel (Taxol®), gemcitabine (Gemzar®), doxorubicin (Adriamycin®), and methotrexate (Jylamvo®) with curcumin. Linking the anti-cancer agents to curcumin optimizes the effectiveness of both agents. The linker breaks once the compound enters a cell (and is safely excreted?).
- The curcumin-linked compounds can overcome many of the limitations of conventional chemotherapies, including by:
- Activating the beneficial immune system within the tumor environment without triggering systemic autoimmune responses
- Delivering anti-oxidant and anti-inflammatory properties that reduce typical negative side effects such as nausea, fatigue, nerve damage, appetite loss, brain fog, etc.
- Crossing the blood-brain barrier that prevents most chemotherapeutics from being effective against brain tumors such as glioblastomas.
- Offering in many cases a more convenient topical application usage experience versus intravenous infusion.
Vascarta-licensed Pancreatic Cancer Technology – Key Finding To Date
- Initial results from testing in typically poorly survivable pancreatic cancer tumors have been extremely positive. Mice were implanted with pancreatic cancer tumor cells. Then the mice were split into 3 groups:
- The red color group only received placebo treatment injected into their tumor cells
- The tumor cells of the blue color group were injected with the novel compound STO-2 which links the proven anti-cancer therapeutic Gemzar® (Gemcitabine) with curcumin
- The tumor cells of the orange color group received STO-2 delivered topically using Vascarta’s patented transdermal gel system, Vasporta™
- As shown below, the tumor cells in the placebo treated mice grew much larger while the tumors of the STO-2 treated mice were much smaller.
- These tumor size reductions are an extremely encouraging result in pancreatic cancer which is poorly survivable.
- Moreover, the strong results for STO-2 delivered topically using Vascarta’s Vasporta™ system provides hope that cancer treatment could be much more conveniently administered topically than via the typical injections/infusions.
